The Evolving Role of Cytokine Therapy for Renal Cell Carcinoma: Past, Present, and Future

Download All
Expert guidance for physicians, nurses, and pharmacists on evolving cytokine therapy for RCC.
Brendan D. Curti, MD


Despite the advance of newer immunotherapies and targeted agents for the treatment of RCC, high-dose IL-2 has an important role in achieving a durable response. Read my thoughts on when to consider it and which patients may benefit the most.

Brendan D. Curti, MD Released: August 24, 2020
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Clinigen Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings